FibroGen’s roxadustat fails a PhIII clinical trial
The biotech FibroGen has hit a bump with its anemia treatment.
On Friday, FibroGen announced that roxadustat failed to hit its primary endpoint in a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
